# VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations

Source: https://onco.cc/key-papers/paper-vision-tepotinib-paik-nejm-2020/  
OnCo record `paper-vision-tepotinib-paik-nejm-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The once-daily MET inhibitor tepotinib shrank tumours in about half of patients with MET exon 14-skipping lung cancer, detected either in tissue or in a blood test, supporting approval and the use of liquid biopsy to find the alteration.

## Summary

Phase 2 study of 152 patients with advanced non-small-cell lung cancer with MET exon 14 skipping detected by liquid or tissue biopsy treated with tepotinib 500 mg daily.

Objective response by independent review was 46 percent overall (48 percent in liquid-biopsy and 50 percent in tissue-biopsy groups) with a median duration of response of 11.1 months; peripheral oedema was the main toxicity.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: New England Journal of Medicine
- Year: 2020
- DOI: 10.1056/NEJMoa2004407
- Authors: Paik PK, Felip E, Veillon R, et al.
- Findings: Objective response 46 percent; median duration of response 11.1 months.; Similar responses whether detected by liquid or tissue biopsy.
- What it means: Tepotinib is an approved alternative to capmatinib for MET exon 14 lung cancer, and the trial validated circulating tumour DNA as a way to find the alteration.
- Caveats: Single-arm; grade 3 or higher peripheral oedema in 7 percent.

## Sources

- N Engl J Med 2020: https://doi.org/10.1056/NEJMoa2004407
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32469185/

## Connected records

- cancers: [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/)
- drugs: [Tepotinib](https://onco.cc/drugs/tepotinib/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)

---
JSON: https://onco.cc/api/v1/entities/paper-vision-tepotinib-paik-nejm-2020.json